S&P 500

5.431,60

-0,04%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

0QQ6

Roche (0QQ6)

Roche Holding Ag

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:LSE:0QQ6

Data	Hora	Fonte	Título	Código	Companhia
15/06/2024	11:00	UK Regulatory	Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma	LSE:0QQ6	Roche Holding Ag
10/06/2024	02:05	UK Regulatory	Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization	LSE:0QQ6	Roche Holding Ag
10/06/2024	02:00	UK Regulatory	European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer	LSE:0QQ6	Roche Holding Ag
07/06/2024	11:40	UK Regulatory	Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk	LSE:0QQ6	Roche Holding Ag
29/05/2024	02:00	UK Regulatory	FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	LSE:0QQ6	Roche Holding Ag
27/05/2024	02:00	UK Regulatory	Changes to the Roche Enlarged Corporate Executive Committee	LSE:0QQ6	Roche Holding Ag
27/05/2024	02:00	UK Regulatory	Wechsel in der erweiterten Konzernleitung von Roche	LSE:0QQ6	Roche Holding Ag
22/05/2024	02:00	UK Regulatory	Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk	LSE:0QQ6	Roche Holding Ag
21/05/2024	02:00	UK Regulatory	FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation	LSE:0QQ6	Roche Holding Ag
16/05/2024	02:00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity	LSE:0QQ6	Roche Holding Ag
15/05/2024	02:00	UK Regulatory	Roche announces FDA approval of one of the first HPV self-collection solutions in the U.S., expanding access and screening options to help eliminate cervical cancer	LSE:0QQ6	Roche Holding Ag
24/04/2024	02:00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche sales increase by 2% (CER) in first quarter with both divisions growing in high single digit ex COVID-19	LSE:0QQ6	Roche Holding Ag
24/04/2024	02:00	UK Regulatory	[Ad hoc-Mitteilung gemäss Art. 53 KR] Verkäufe der Roche-Gruppe steigen im ersten Quartal um 2% (CER); beide Divisionen Pharma und Diagnostics wachsen im hohen einstelligen Bereich ohne COVID-19-Produkte	LSE:0QQ6	Roche Holding Ag
19/04/2024	02:00	UK Regulatory	FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer	LSE:0QQ6	Roche Holding Ag
17/04/2024	03:00	UK Regulatory	Roche’s subcutaneous OCREVUS one-year data demonstrates near-complete suppression of clinical relapses and brain lesions in patients with progressive and relapsing forms of MS	LSE:0QQ6	Roche Holding Ag
15/04/2024	02:00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche’s Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study	LSE:0QQ6	Roche Holding Ag
11/04/2024	02:00	UK Regulatory	Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis	LSE:0QQ6	Roche Holding Ag
26/03/2024	13:45	UK Regulatory	Roche receives FDA approval for the first molecular test to screen for malaria in blood donors	LSE:0QQ6	Roche Holding Ag
12/03/2024	09:30	UK Regulatory	Assemblée générale 2024 de Roche	LSE:0QQ6	Roche Holding Ag
12/03/2024	09:30	UK Regulatory	Roche Generalversammlung 2024	LSE:0QQ6	Roche Holding Ag
12/03/2024	09:30	UK Regulatory	Roche Annual General Meeting 2024	LSE:0QQ6	Roche Holding Ag
05/03/2024	09:30	UK Regulatory	Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care	LSE:0QQ6	Roche Holding Ag
25/02/2024	16:00	UK Regulatory	New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies	LSE:0QQ6	Roche Holding Ag
16/02/2024	13:24	UK Regulatory	FDA approves Xolair as first and only medicine for children and adults with one or more food allergies	LSE:0QQ6	Roche Holding Ag
01/02/2024	03:03	UK Regulatory	New long-term data for Roche’s Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)	LSE:0QQ6	Roche Holding Ag
01/02/2024	03:00	UK Regulatory	[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline	LSE:0QQ6	Roche Holding Ag
01/02/2024	03:00	UK Regulatory	[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche übertrifft Guidance für 2023 und erzielt trotz stark rückläufigem COVID-19-Umsatz Verkaufswachstum von 1% (CER)	LSE:0QQ6	Roche Holding Ag
01/02/2024	03:00	UK Regulatory	[Annonce événementielle au sens de l’art. 53 RC] Roche dépasse les projections et affiche une croissance des ventes de 1 % (TCC) en 2023, malgré un net recul des ventes lié au COVID-19	LSE:0QQ6	Roche Holding Ag
23/10/2023	08:18	IH Market News	Monday’s Wall Street Highlights: Philips, Chevron, Textainer, Okta, Roivant, and more	LSE:0QQ6	Roche Holding Ag